Patient-focussed outcomes in acromegaly by Mirtha Guitelman et al.
Patient-focussed outcomes in acromegaly
Mirtha Guitelman • Alin Abreu •
Ana Laura Espinosa-de-los-Monteros •
Moise´s Mercado
Published online: 20 September 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Background Health-related quality of life (QoL) is
severely impaired in acromegaly due to the physical and
psychological consequences of the disease. Pharmacolog-
ical and surgical treatments, when available, can improve
QoL and life expectancy.
Case description A 34-year-old male with uncontrolled
acromegaly due to a large and invasive macroadenoma,
which could not be resected by transsphenoidal surgery.
Over 9 years, he had limited access to pharmacological
interventions and persisted with clinically and biochemi-
cally active disease, with severe co-morbidities and a poor
QoL, which eventually lead to a premature sudden death.
Conclusion This case highlights the impact that active
acromegaly has when treatment resources are limited. We
review the factors contributing to poor QoL in this disease,
with special reference to the Latin American scenario.
Keywords Acromegaly  Pituitary  Latin America 
GH  IGF-1  Quality of life  Somatostatin analogs
Introduction
Health-related quality of life (QoL) is known to be severely
impaired in patients with acromegaly [1–3]. Several vali-
dated tools have been used to assess QoL in patients with
acromegaly, including one disease-specific instrument
called the acromegaly quality of life questionnaire (Acro-
QoL), which involves 22 items concerning the physical
dimension of the disease and two separate psychological
dimensions connected with appearance and personal rela-
tions [4, 5]. Although improvements in QoL can be achieved
with pharmacological and surgical interventions, physical
and psychological residual morbidity and worse coping
strategies can lead to persistently impaired QoL, even in
acromegalic patients with long-term biochemical remission
[2, 3, 6–11]. As such, QoL considerations in both treated and
untreated patients are important for the long-term manage-
ment of acromegaly. In this article, we provide a brief
overview of the factors contributing to poor QoL in acro-
megaly, with reference to a Latin American case study, and
discuss how QoL can be improved.
QoL in active and controlled acromegaly
The available evidence from both disease-specific and gen-
eric QoL tools consistently shows that patients with acro-
megaly (even those in biochemical remission) have reduced
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QoL compared to matched populations without acromegaly
[1, 2, 5, 6, 8, 12, 13]. The most affected aspects of QoL in
acromegaly are related to appearance and the least affected
are related to personal relations [2, 5, 14].
Several factors appear to predict worse QoL in acro-
megaly, including disease activity, female gender, older
age, longer disease duration, the presence of specific
symptoms/comorbidities, certain treatment modalities and
delays in diagnosis [2, 5–7, 15]. In terms of disease
activity, some (but not all) studies have shown that patients
in biochemical remission have significantly better QoL (at
least in some dimensions) than patients with persistent
disease, or that improvements in biochemical parameters
correlate with improved QoL [1, 5, 8, 11, 12, 14, 16–19].
However, it should also be noted that patients with acro-
megaly who develop growth hormone deficiency (GH)
after treatment also have decreased QoL [20].
Several disease-specific symptoms or comorbidities of
acromegaly are associated with poor QoL. Joint-related
complications (leading to pain and immobility), in partic-
ular, are frequently encountered in acromegaly and have
been shown to have a significant negative impact on QoL
[7, 21–25]. These complications may persist during bio-
chemical remission and represent a major cause of mor-
bidity [7, 23, 24]. Sleep apnea syndrome is another
common complication of acromegaly that has a negative
influence on QoL [11, 26]. Other comorbidities such as
depressive mood and hypertension may also be associated
with poor QoL in acromegaly [11, 22].
Among treatment modalities, radiotherapy in particular
has been associated with reduced QoL [7, 27]. In one study
that followed patients with stable biochemical control over
4 years, previous radiotherapy was the predominant pre-
dictor of progressive impairments in QoL [27]. This may
relate to the effects of GH deficiency, among other defi-
ciencies, that can occur with definitive therapy for acro-
megaly using irradiation or surgery [3, 20].
Fig. 1 MRI scans of pituitary tumor at diagnosis (December 1994, left) and 9 years after surgery and radiotherapy without medical treatments
(January 2008, right)
Case study: 9 years of uncontrolled disease without appropriate
medical therapy: a case for poor QoL (Mirtha Guitelman, MD)
A 34-year old man presented with headaches, acral enlargement,
oily skin, sleep apnea, fatigue, hyperhidrosis and generalized
joint pain
All these symptoms started 5 years prior to the first consultation
The patient had no relevant background
Physical exam revealed
Thyroid: 30 g
Typical facial features: lip, nose and tongue enlargement
Prognathism
Acral enlargement (finger size: 33)
No Hypertension
Endocrinological lab results (Nov 1993)
Baseline and post-glucose GH 50 lg/L
IGF-1: 700 lg/L (normal for age B500 lg/L)
Prolactin: 200 lg/L (normal 5–20 lg/L)
Total T4: 1.2 nmol/L (6.9 lg/dL); TSH: 1.6 mIU/L
Testosterone: 6.6 nmol/L (190 ng/dL)
LH: 3 IU/L; FSH: 2.8 IU/L
Normal glucose metabolism
MRI at diagnosis (Dec 1994)
Voluminous sellar mass with sphenoid sinus invasion, extension
in the suprasellar cistern causing displacement of the pituitary
stalk and invasion into the right cavernous sinus (Fig. 1)
Complementary studies
Echocardiogram: Mild dilated left ventricle with appropriate
systolic function. Left and right ventricular dilatation
Treatments
In 1995 he received intermittently subcutaneous SSAs
300 lg/day and bromocriptine for 6 months with no changes
in IGF-1 levels or tumor size
Due to the lack of drug availability and lack of response, the
patient was sent to surgery
Transsphenoidal surgery (Aug 1996)
Pathology: GH-Prolactin co-secreting tumor
GH after surgery: 51 lg/L
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Case discussion
This 49-year-old man with acromegaly diagnosed at age
34, never achieved normal levels of IGF-1 and GH despite
two surgeries and radiotherapy after initially receiving
suboptimal pharmacological therapy. He subsequently
received no treatment at all over a period of 9 years fol-
lowed by further suboptimal pharmacological therapy and
died early due to lack of disease control. Patients with
acromegaly have significantly increased mortality, even
after transsphenoidal surgery [28]. However, achievement
of biochemical control has been shown to significantly
improve life expectancy [29].
Apart from the patient’s reduced life span another
important aspect of the patient’s poor disease control was
the severe debilitating complications of acromegaly that he
had to endure for many years. As a consequence, it is
highly likely that this patient experienced profound long-
term impairments in QoL derived from his multiple sys-
temic complications. The presence of severe arthropathy,
in particular, is known to be a major cause of morbidity and
immobility in acromegaly and has a marked negative
impact on QoL [24, 25]. Other factors, such as sleep apnea
and psychological aspects associated with his acromegalic
appearance may also have reduced the patient’s QoL. The
patient is also an illustrative example of the consequences
of a delayed diagnosis; had his condition been detected
earlier, he would have undoubtedly had a different and
better outcome.
Due to the invasive nature of this patient’s tumor,
pharmacological therapy with SSAs would have been the
primary treatment of choice, but these agents were only
available intermittently for a short period after diagnosis
and this option could not be implemented appropriately.
The question is whether long-term pharmacological treat-
ment with SSAs or other pharmacological therapies could
have changed the QoL of this patient, as well as improving
his life expectancy.
Improving QoL in acromegaly
As noted above, there is some evidence to suggest that
patients with biochemically controlled acromegaly have
significantly better QoL (at least on some subscales) than
patients with persistent disease, although not all studies
have found a strong association [1, 5, 8, 11, 12, 14, 16–19].
One study suggests that the best QoL in treated patients
seems to be achieved if insulin-like growth factor-1 (IGF-
1) is normalized and the GH nadir (during an oral glucose
tolerance test) is targeted to levels less than 1.0 lg/L but
above 0.3 lg/L [8].
Several studies have also shown consistently that treat-
ment with surgery or long-acting SSAs is associated with
significant improvements in QoL [30–35]. This might be
expected, as these treatments can provide significant
improvements in symptoms known to be associated with
poor QoL, especially in the frequency and severity of sleep
apnea episodes [26]. With the exception of radiotherapy,
which is generally associated with poorer QoL, it is hard to
distinguish any notable differences on overall QoL
between different treatment modalities [14]. Randomized
Transcranial surgery (Apr 1997)
GH after surgery: [30 lg/L
Hypogonadotrophic hypogonadism
Normal thyroid and adrenal function
Radiotherapy 5,000 CGy (May 1998)




Rest of anterior pituitary hormones normal
Bromocriptine and somatostatin analogs were indicated
The patient returned (Jan 2008) after 9 years without any
treatment
Joint stiffness, paresthesia, arthropathy (osteoarthritis, needed a
walking stick), macroglossia, severe obstructive sleep apnea
and headache
Acral enlargement, increased sweating
Signs and symptoms of Hypopituitarism
Hormonal evaluation after 9 years without treatments
GH: 19.9 lg/L; IGF-1: 640 lg/L (normal for age 101–303 lg/L)
Prolactin: 860 lg/L
LH: 0.2 IU/L; FSH: 0.5 IU/L; Testosterone: 0.3 nmol/L
(0.1 ng/mL)
Cortisol: 28 nmol/L (1 lg/dL)
Free T4: 8.4 pmol/L (0.65 ng/dL); TSH: 2.7 mIU/L
Active disease plus complete Hypopituitarism
For MRI scan in Jan 2008, 9 years after surgery and radiotherapy








The patient didn’t return to the hospital again after February
2008, in spite of attempts to contact him for follow-up
The patient died suddenly in January 2010 at age of 49
At the time of death, he had been on regular L-T4,
hydrocortisone and cabergoline, as well as irregular
testosterone replacement
He never received somatostatin analogs due to difficulties
obtaining the drug
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comparative studies in newly diagnosed patients suggest
that long-acting SSAs and surgery provide similar levels of
QoL when used as first-line therapy [32, 35]. Pharmaco-
logical combination therapy (e.g., adding pegvisomant to
an SSA) may also provide better improvements in QoL
independently of having better biochemical control [36].
It should be emphasized that, although clinically and
biochemically effective, some SSAs need to be injected by
a properly trained professional, and thus, patients are
required to visit the hospital or medical office every few
weeks. Although usually not a major problem, this may
generate more psychological distress, social fears and a
poorer sense of well-being and may hamper improvements
in QoL [17, 37]. Clinical trial and observational study
evidence suggests that patients prefer the option to
administer SSAs themselves or by a partner at home rather
than by a healthcare professional, and this does not appear
to compromise efficacy or safety [38–42]. Further evidence
also suggests that patients also prefer longer intervals
between injections, and this also appears to be achievable
with certain SSAs without loss of efficacy [41, 43].
It has been suggested that targeted psychosocial inter-
ventions, such as cognitive behavioral therapy, self-man-
agement training, and information on the negative effects
of the disease might help biochemically controlled patients
with acromegaly to use more active coping strategies,
which might lead to improvements in QoL [10]. In a recent
study, greater diagnostic delay by the physician (relative to
a patient first seeking medical advice) was associated with
reduced psychological QoL, depression, sleep disturbances
and impaired body image, suggesting that improved phy-
sician awareness of acromegaly (leading to earlier diag-
nosis) may also help to improve QoL [15]. To our
knowledge only one Latin-American study has evaluated
QoL in acromegaly using an adapted version of the Ac-
rQoL questionnaire [46]. This study from a tertiary care
center in Mexico City found that the 50 patients with
acromegaly have reduced scores in all scales of the Acro-
Qol (physical, psychological, appearance and interpersonal
relationships) when compared to controls [46]; yet, no
differences in any of these scales were found between
active and controlled patients, perhaps due to the relatively
low number of patients [46].
Conclusions
Patients with long-term uncontrolled acromegaly, as in our
case study, are likely to have severe acromegalic features,
symptoms and comorbidities and consequently signifi-
cantly impaired QoL and reduced life expectancy. How-
ever, there are many unanswered questions about the
benefits of controlled compared with uncontrolled
acromegaly regarding QoL and other factors, such as costs
and morbidities [14, 19]. For instance, normalization of
levels of IGF-1 and GH do not necessarily reflect optimal
QoL or symptom relief [44]. As such, QoL considerations
in both treated and untreated patients are important for the
long-term management of acromegaly and it has been
suggested that simplified measures of QoL may provide a
reliable additional measurement of disease activity in
everyday clinical practice [44].
It is also possible that reduction in tumor mass (which
may be independent of biochemical control with SSAs
[45]) has the potential to improve QoL, although this
remains to be further investigated. With the available evi-
dence it is hard to distinguish any notable consistent dif-
ferences in QoL between pharmacological therapy and
surgery (at least in the first-line setting), whereas radio-
therapy appears to be associated with a reduced QoL [14,
32, 35]. However, some factors associated with pharma-
cological therapy, such as regular hospital visits for drug
administration, may have an adverse impact on QoL, and
there is the potential to minimize this through the use of
drug formulations that require less frequent dosing and/or
can be administered at home without the help of a
healthcare professional. Longer-acting drugs may also have
the potential to improve QoL through tumor shrinkage.
Prompt diagnosis and targeted psychosocial interventions
may also be an important factors leading to better QoL.
In summary, in patients with active acromegaly, as well
as those in remission, attention to QoL issues is highly
recommended [3]. The best balance of efficacy, cost and
QoL will likely be achieved with an individualized
approach to therapy, based on available pharmacological,
surgical and radiotherapeutic resources [14].
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